OMAHA, Neb., Aug. 4, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:
Transgenomic, Inc. Second Quarter 2011 Financial Results and Business Update Conference Call
Thursday, August 11, 2011 @ 5:00 p.m. Eastern
Live over the Internet -- Simply log on to the web at the address above.
Investor Relations, 402-452-5400
To access the call via telephone, call 800-895-0198 from the U.S. or Canada or 785-424-1053 for international participants and enter conference ID TRANS. A telephone replay will be available from 6:00 p.m. Eastern Time on August 11, 2011 through 11:59 p.m. Eastern Time on August 25, 2011 by dialing 800-374-1375 (domestic) or 402-220-0682 (international).
About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The company has three complementary business divisions: Transgenomic Pharmacogenomic Services is a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Transgenomic Clinical Laboratories specializes in molecular diagnostics for cardiology, neurology, mitochondrial disorders, and oncology. Transgenomic Diagnostic Tools produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The company actively develops and acquires new technology and other intellectual property that strengthen its leadership in personalized medicine.
SOURCE Transgenomic, Inc.